Brief: Newron Announces Interim Results From Its Exploratory Clinical Trial For Evenamide As Add-On Therapy For Treatment-Resistant Schizophrenia

Newron Pharmaceuticals SpA

03/01/2023 13:13

Jan 3 (Reuters) - Newron Pharmaceuticals SpA  NWRN.S :
    * NEWRON ANNOUNCES STRIKING SIX-MONTH INTERIM RESULTS FROM
ITS
EXPLORATORY CLINICAL TRIAL EVALUATING EVENAMIDE AS ADD-ON
THERAPY FOR PATIENTS WITH TREATMENT-RESISTANT SCHIZOPHRENIA
    * NEWRON PHARMACEUTICALS SPA-STATISTICALLY SIGNIFICANT,
CLINICALLY
MEANINGFUL IMPROVEMENTS OVER BASELINE SEEN ACROSS EFFICACY
ENDPOINTS AFTER 6 MONTHS
    * NEWRON PHARMACEUTICALS SPA - CONTINUED IMPROVEMENT WAS
SEEN WHEN
COMPARED WITH RESULTS AFTER SIX WEEKS
    * NEWRON PHARMACEUTICALS SPA - NEWRON PLANS TO COMMENCE A
PIVOTAL
STUDY IN TREATMENT-RESISTANT SCHIZOPHRENIA IN 2023
    * NEWRON PHARMACEUTICALS SPA - EXPECTS TO ANNOUNCE FULL
RESULTS
FROM STUDY IN MARCH 2023

Source text for Eikon:  ID:nBw2GTK2ga 
Further company coverage:  NWRN.S 
 ((Reuters.Briefs@thomsonreuters.com;))